News | October 23, 2007

Isosmolar Visipaque Demonstrates Low Incidence of Contrast-Induced Nephropathy

October 24, 2007 — Study results presented this week at the Transcatheter Cardiovascular Therapeutic (TCT) annual meeting in Washington D.C., demonstrated that the use of GE's isosmolar contrast medium Visipaque (iodixanol) resulted in a statistically significantly lower rate of contrast-induced nephropathy (CIN) than the low osmolar nonionic contrast agent ioversol, according to the company.
The study was conducted in 250 patients with diabetes who underwent either coronary angiography to determine if there was disease in the arteries, or percutaneous coronary intervention to improve circulation of diseased arteries that supply blood to the heart muscle.
The authors reported the use of the isosmolar contrast medium Visipaque resulted in a statistically significantly lower rate of CIN at 72 hours following contrast medium administration when compared with the low osmolar nonionic contrast agent ioversol (2.5% vs 8.3%; p = 0.047).
Study investigators also noted that in the group of patients at highest risk, those who underwent a percutaneous coronary intervention procedure and received higher amounts of a contrast medium, Visipaque use also resulted in significantly lower rate of CIN at 72 hours than ioversol (2% vs 13.5%; p = 0.02).

For more information:

Related Content

Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
OptiStar Elite injector
Feature | Contrast Media Injectors | March 07, 2018 | Grand View Research Inc.
The global contrast media injectors market is expected to reach $1.4 billion by 2025, growing at a compound annual...
TriHealth in Cincinnati

TriHealth in Cincinnati.

Sponsored Content | Case Study | Contrast Media Injectors | March 06, 2018
The continuing search for advantages to improve workflow has radiology departments constantly searching for new...
Guerbet Presents Contrast&Care Injection Management Solution at ECR 2018
News | Contrast Media | February 28, 2018
February 28, 2018 — Guerbet will present its new Contrast&Care application, as well as other...
Guerbet to Participate in French Interventional Radiology Conference
News | Contrast Media | October 10, 2017
Guerbet announced it will be taking part in the 65th edition of the Journées Francophones de Radiologie (JFR) that will...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Experience at 3 Sites Utilizing Syringe-Less Contrast Injectors
Sponsored Content | Case Study | Contrast Media Injectors | April 13, 2017
The volume of computed tomography (CT) imaging exams continues to grow in the United States,[2] adding pressure to...
contrast media
Feature | Contrast Media Injectors | March 02, 2017 | By Jeff Zagoudis
With medical imaging use on the rise, contrast media use is expected to grow as well, according to a May 2016 report...
contrast media
News | Contrast Media | December 09, 2016
At the 2016 Annual Meeting of the Radiological Society of North America (RSNA 2016), Bracco Diagnostics Inc. showcased...